SecBot SecBot
Biotech Drug Report Generated Nov 16, 2026

IXCHIQ

VALN·Valneva SE
BEARISH
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed in the EU, Canada, Brazil and select other markets (approved November 2023 in the US, but US and UK authorizations have been withdrawn).
Why 4/10
IXCHIQ is an approved and marketed vaccine in the EU, Canada and Brazil but has no pending regulatory decision or pivotal readout scheduled in the next 12 months (the US BLA and UK marketing authorization were withdrawn). The next company-level catalyst is the nine-month 2026 financial results on November 24, 2026, which is a financial reporting event, not a drug-specific binary catalyst.
Actionable Insight BEARISH

IXCHIQ's commercial future hinges on whether Valneva can rebuild regulatory trust after the US and UK withdrawals. The positive five-year durability data (94% seroresponse) supports the vaccine's efficacy case, but safety concerns remain the dominant overhang. Valneva reports nine-month 2026 results on November 24, which will provide the clearest read on IXCHIQ's ongoing revenue contribution from EU, Canada and Brazil markets.

Price Chart

Loading chart...

Executive Summary

IXCHIQ (VLA1553) is Valneva's single-dose, live attenuated chikungunya vaccine that was the first FDA-approved vaccine against the mosquito-borne virus in November 2023. However, the product has been severely impacted by safety issues: the FDA suspended its US license in August 2025 after reports of serious adverse events including encephalitis deaths, leading Valneva to voluntarily withdraw the US BLA/IND in January 2026. The UK's MHRA revoked marketing authorization in October 2026. IXCHIQ remains approved in the EU, Canada, Brazil and other markets, and positive five-year durability data (94% seroresponse) was reported in November 2026. The vaccine generated EUR 8.4 million in H1 2026 sales, a modest contributor to Valneva's overall revenue.

How It Works

IXCHIQ is a live attenuated vaccine, meaning it contains a weakened version of the chikungunya virus that cannot cause disease in healthy people but trains the immune system to recognize and fight the real virus. It is given as a single injection and prompts the body to produce protective antibodies against chikungunya, a mosquito-borne virus that causes fever and severe joint pain.

Trial Status

IXCHIQ received FDA accelerated approval in November 2023 based on pivotal Phase 3 data. Five-year follow-up data published in November 2026 showed 94% seroresponse persistence. The vaccine was studied in Phase 3 trials including VLA1553-301 (adults) and VLA1553-321 (adolescents).

The Two-Sided Case

▲ Bull Case5
First-to-market advantage: IXCHIQ was the first FDA-approved chikungunya vaccine and remains approved in the EU, Canada, Brazil and other markets.
Durable efficacy: Five-year follow-up data (November 2026) showed 94% of recipients maintained neutralizing antibody titers above the seroresponse threshold after a single dose.
Comparable protection in elderly: Antibody persistence in adults 65+ was comparable to younger adults, supporting use in the highest-risk age group.
Outbreak demand: Chikungunya outbreaks continue globally, creating potential demand in endemic regions and for travelers to those areas.
Valneva has other revenue streams: Ixiaro (Japanese encephalitis) and Dukoral (cholera) vaccines provide a diversified revenue base beyond IXCHIQ.
▼ Bear Case5
US market lost: FDA suspended the license in August 2025 after reports of serious adverse events including encephalitis deaths; Valneva voluntarily withdrew the BLA/IND in January 2026.
UK market revoked: MHRA revoked marketing authorization in October 2026 after a benefit-risk review found risks outweighed benefits for travelers.
Safety overhang: Serious adverse events consistent with chikungunya-like illness, including hospitalizations and deaths, primarily in older adults with underlying conditions, have damaged the product's reputation.
EMA safety action: European Medicines Agency's PRAC recommended updating product information to reflect aseptic meningitis risk (March 2026).
Limited revenue: IXCHIQ generated only EUR 8.4 million ($9.4 million) in H1 2026, a small fraction of Valneva's total revenue guidance of EUR 145-160 million.

Upcoming Catalysts

  • Nine-month 2026 financial results on November 24, 2026, which will include IXCHIQ revenue contribution.
  • Potential expansion in Brazil and other endemic-country markets where Valneva is seeking approvals.
  • Any further regulatory actions by EMA or other health authorities regarding the safety profile.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Valneva SE 6-K VALN ·Originating report

Sources · 12

Hover a chip for the title
1 msn.com2 markets.businessinsider.com3 rttnews.com4 msn.com5 marketwatch.com6 streetinsider.com7 fiercepharma.com8 fiercepharma.com9 medscape.com10 seekingalpha.com11 marketscreener.com12 seekingalpha.com